Isaac Barchas - Oct 27, 2023 Form 4 Insider Report for Immunome Inc. (IMNM)

Role: Director
Signature: /s/ Sandra G. Stoneman, Attorney-in-fact
Stock symbol: IMNM
Transactions as of: Oct 27, 2023
Transactions value $: $0
Form type: 4
Date filed: 10/31/2023, 06:35 PM
Previous filing: Oct 12, 2023
Next filing: Jun 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMNM	Stock option (right to buy)	Award	$0	+41.5K		$0.00	41.5K	Oct 27, 2023	Common Stock	41.5K	$8.73	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Mr. Barchas waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the "New NED Compensation Policy"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Barchas' initial grant under the New NED Compensation Policy.
F2	The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.

Content

Mr. Barchas waived the initial grant provided for under the Company's non-employee director compensation policy in effect on the date he joined the Company's board of directors pending the adoption of an amended and restated non-employee director compensation policy (the "New NED Compensation Policy"). On October 27, 2023, the compensation committee of the Company's board of directors adopted and approved the New NED Compensation Policy. The above reflects Mr. Barchas' initial grant under the New NED Compensation Policy.

The options vest in 12 quarterly installments over three years, commencing on October 2, 2023 and continuing thereafter on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.